Top Banner
Leeds Biomedical Research Centre PMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University of Leeds Honorary Consultant, Leeds Teaching Hospitals NHS Trust
12

PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

Mar 16, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

Leeds Biomedical

Research Centre

PMR and GCA research: what’s next?

Dr Sarah Mackie, rheumatologistAssociate Professor, University of Leeds

Honorary Consultant, Leeds Teaching Hospitals NHS Trust

Page 2: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

Disclaimer

The views expressed are those of the

presenter and not necessarily those of the

NHS, the NIHR or the Department of

Health and Social Care.

Page 3: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University
Page 4: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

• Experimental approach – clinical trials

– “evidence based medicine”

• Observational approach – “basic science”

– understanding of the biological basis of

disease (”lab science”)

– using “big data” to understand patterns of

disease in populations (epidemiology)

• Approaches drawn from social science:

qualitative, mixed methods appraoches

Types of research

Page 5: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University
Page 6: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

Hierarchy of evidence

Page 7: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

tocilizumab

Page 8: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

Horizon scanning

• clinicaltrials.gov• EudraCT

Page 9: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

Name (company) Country Intervention n

GiAnT France Anakinra vs placebo 70

UGCA US Ustekinumab (single arm only) 20

tbc (Sanofi) worldwide Sarilumab vs placebo 360

(Lilly) US Bariticinib (single arm only) 15

(Kiniksa) worldwide Mavrilimumab vs placebo 60

GCA

All information in public domain and taken from: • clinicaltrials.gov• EudraCT

searches last updated 7 Sept 2018

Page 10: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

Name (company) Country Intervention n

SEMAPHORE France TCZ vs placebo 100

PMR-SPARE Austria TCZ vs placebo 32

PMRLEFRCT Netherlands LEF vs placebo 94

tbc (Sanofi) worldwide Sarilumab vs placebo 280

ALORS France Abatacept vs placebo 34

PMR

All information in public domain and taken from: • clinicaltrials.gov• EudraCT

searches last updated 7 Sept 2018

Page 11: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

• Clinical trials

– Drug trials

– Trials of non-drug approaches (exercise, diet)

• Lab science

– New technologies for identifying molecules,

cells, processes involved in the diseases

• Epidemiology

– Routinely-collected healthcare data

• Qualitative / social science

More than just drug trials

Page 12: PMR and GCA research: what’s next? - PMR GCA talk Sept 2018 - Dr Sarah Mackie.pdfPMR and GCA research: what’s next? Dr Sarah Mackie, rheumatologist Associate Professor, University

• Thank you for listening

• Any questions?